Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on Acurx Pharmaceuticals and keeping the price target at $31.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matthew Keller has given his Buy rating due to a combination of factors that highlight the promising outlook for Acurx Pharmaceuticals. A key reason is the positive opinion from the European Medicines Agency’s Pediatric Committee on the Pediatric Investigation Plan for ibezapolstat (IBZ), which is a crucial step for its use in children with C. difficile infections. This regulatory milestone is significant as it positions IBZ favorably for its upcoming Phase 3 trials and supports the pathway for future marketing authorization applications in both the EU and the US.
Additionally, IBZ has shown impressive clinical efficacy in previous Phase 2 trials, with a high Clinical Cure rate of 96%, which surpasses the historical cure rate of vancomycin. The success in these trials, coupled with the favorable regulatory feedback, underscores the potential of IBZ as a treatment for C. difficile infections. These developments collectively contribute to Keller’s optimistic outlook and the Buy rating for Acurx Pharmaceuticals.